Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 4
2014 1
2015 3
2016 3
2017 4
2018 9
2019 4
2020 11
2021 8
2022 22
2023 17
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
ASO Visual Abstract: High Community-Level Social Vulnerability is Associated with Worse Recurrence-Free Survival Following Resection of Extremity and Truncal Soft-Tissue Sarcoma.
Traweek RS, Lyu H, Witt RG, Snyder RA, Nassif EF, Krijgh DD, Smith JM, Tilney GS, Feng C, Chiang YJ, Torres KE, Roubaud MJ, Scally CP, Hunt KK, Keung EZ, Mericli AF, Roland CL. Traweek RS, et al. Among authors: keung ez. Ann Surg Oncol. 2024 Mar 28. doi: 10.1245/s10434-024-15201-3. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38546800 No abstract available.
The Future of Targeted Therapy for Leiomyosarcoma.
Denu RA, Dann AM, Keung EZ, Nakazawa MS, Nassif Haddad EF. Denu RA, et al. Among authors: keung ez. Cancers (Basel). 2024 Feb 26;16(5):938. doi: 10.3390/cancers16050938. Cancers (Basel). 2024. PMID: 38473300 Free PMC article. Review.
High Community-Level Social Vulnerability is Associated with Worse Recurrence-Free Survival (RFS) After Resection of Extremity and Truncal Soft Tissue Sarcoma.
Traweek RS, Lyu HG, Witt RG, Snyder RA, Nassif EF, Krijgh DD, Smith JM, Tilney GS, Feng C, Chiang YJ, Torres KE, Roubaud MJ, Scally CP, Hunt KK, Keung EZ, Mericli AF, Roland CL. Traweek RS, et al. Among authors: keung ez. Ann Surg Oncol. 2024 Feb 23. doi: 10.1245/s10434-024-15074-6. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38396039
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma.
Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N. Roland CL, et al. Among authors: keung ez. Nat Cancer. 2024 Apr;5(4):625-641. doi: 10.1038/s43018-024-00726-z. Epub 2024 Feb 13. Nat Cancer. 2024. PMID: 38351182 Clinical Trial.
Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes.
Cass S, Cope B, Bishop AJ, Chiang YJ, Ashleigh Guadagnolo B, Farooqi A, Morrison W, Witt RG, Seervai RNH, Garden AS, Fuller CD, Goepfert RP, Ross M, Gershenwald JE, Wong M, Aung PP, Keung EZ, Mitra D. Cass S, et al. Among authors: keung ez. Radiother Oncol. 2023 Nov;188:109892. doi: 10.1016/j.radonc.2023.109892. Epub 2023 Sep 1. Radiother Oncol. 2023. PMID: 37659660
Targeting the Molecular and Immunologic Features of Leiomyosarcoma.
Cope BM, Traweek RS, Lazcano R, Keung EZ, Lazar AJ, Roland CL, Nassif EF. Cope BM, et al. Among authors: keung ez. Cancers (Basel). 2023 Mar 31;15(7):2099. doi: 10.3390/cancers15072099. Cancers (Basel). 2023. PMID: 37046760 Free PMC article. Review.
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Amaria RN, et al. Among authors: keung ez. Nature. 2023 Mar;615(7953):E23. doi: 10.1038/s41586-023-05892-1. Nature. 2023. PMID: 36894629 Free PMC article. No abstract available.
77 results